GRID Hamilton Rating Scale For Depression--Brazilian Portuguese Version

Henrique-Araújo, Ricardo; Osório, Flávia L.; Ribeiro, Marcos Borges; Monteiro, Ivandro Soares; Williams, Janet B. W.; Kalali, Amir H; Crippa, José Alexandre S; Oliveira, Irismar Reis de

doi:10.1037/t61109-000

Cited by 5 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Relevant individual data were recorded: age, gender, ethnicity, target antidepressant drug (FLU) and corresponding dosing schedule, last dosing time, duration of the depressive episode and of the antidepressant treatment, previously used antidepressant drug(s) and eventual reasons of its discontinuation, comorbidities and comedication. Depression severity and remission were assessed by the 17-item Hamilton Depression Rating Scale (HAMD) and antidepressant adverse effects by the Antidepressant Side-Effect Checklist (ASEC; Hamilton, 1960;Henrique-Araújo et al, 2014;Uher et al, 2009). A venous blood sample (10 mL) was collected in EDTA-K 3 tubes (non-vacuum blood collection tubes EDTA-K3, 5 mL, Automed, Italy) for therapeutic drug monitoring of FLU and NFLU and genotyping of the CYP2C9, CYP2C19, CYP2D6, and ABCB1 genes.…”

Section: Subjects and Study Designmentioning

confidence: 99%

Pharmacogenetics and therapeutic drug monitoring of fluoxetine in a real-world setting: A PK/PD analysis of the influence of (non-)genetic factors.

Magalhães

Alves

Fortuna

et al. 2020

Experimental and Clinical Psychopharmacology

View full text Add to dashboard Cite

This work presents the GnG-PK/PD-AD study-a pharmacokinetics/pharmacodynamics (PK/PD) analysis of the impact of genetic and nongenetic factors on the treatment with the antidepressant fluoxetine (FLU)-with a focus on potential biomarkers. Seventy-nine depressed patients treated with FLU were recruited and clinically characterized in the scope of the study. Clinical outcomes, including remission and antidepressant adverse effects were assessed by means of the Hamilton Depression Rating Scale and the Antidepressant Side-Effect Checklist, respectively. Patients were submitted to therapeutic drug monitoring of FLU and norfluoxetine and genotyping of the CYP2C9, CYP2C19, CYP2D6, and ABCB1 genes. A multivariate analysis was used to evaluate the impact of genetic and nongenetic factors on the This article was published Online First November 21, 2019.

show abstract

Section: Subjects and Study Designmentioning

confidence: 99%

Pharmacogenetics and therapeutic drug monitoring of fluoxetine in a real-world setting: A PK/PD analysis of the influence of (non-)genetic factors.

Magalhães

Alves

Fortuna

et al. 2020

Experimental and Clinical Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…The study subjects answered a questionnaire through a face-to-face interview, containing questions related to sociodemographic and clinical aspects. Patients underwent psychiatric evaluation where psychometric assessment instruments were applied: the GRID-HAMD21 scales (33) , which assessed the severity of symptoms during the last week, the Childhood Trauma Questionnaire (CTQ) (34)(35)(36) which assesses the history of early stress and the BSI which assessed the presence of suicidal ideation (37) .…”

Section: Clinical Assessmentsmentioning

confidence: 99%

Estudo de associação entre polimorfismos genéticos e níveis plasmáticos do VEGF, FLT1, KDR e o risco para depressão

Nunes¹

View full text Add to dashboard Cite

Gratidão à Deus por se fazer tão presente em minha vida e me permitir experenciar momentos tão especiais, privilegiados e com as pessoas certas em meu caminho. Agradeço infinitamente aos meus pais por todo amor, carinho, educação, paciência e apoio me dedicados ao longo destes 30 anos. Muito obrigada aos meus amados irmãos pelo companheirismo, partilha e amor em nossa jornada fraterna aqui na Terra, vocês me fizeram uma pessoa menos egoísta e me deram pela primeira vez a referência de viver em grupo respeitando nossas diferenças e desfrutando da nossa micro diversidade. Obrigada à Lôlô que mal pode se dar conta do quão bem ela me faz só de ficar do meu lado me observando trabalhar por horas na frente do computador e me fazendo companhia.À todas as pessoas que convivem com a depressão, em especial àquelas que participaram deste estudo, as quais generosamente aceitaram este convite e que têm tentado se superar a cada dia mesmo diante de muitas dificuldades! Ao meu orientador Prof. Dr. Riccardo Lacchini o qual não mediu esforços para que eu me inserisse em seu grupo de pesquisa da melhor maneira possível, já que vim de outro estado e de outra instituição, saindo completamente da minha zona de conforto. Serei eternamente grata por todas as oportunidades que me foram ofertadas, pela paciência e generosidade em partilhar tanto conhecimento, humanidade e bom senso no nosso dia-a-dia de trabalho e sempre me dando todo apoio e incentivo para os estudos. Se tornou uma das maiores referências para mim como professor e pesquisador. Muito obrigada aoLucas que aceitou o convite e desafio da co-orientação deste trabalho e sempre trazendo ideias, sugestões e correções importantes, o que acrescentou muito no desenvolvimento e qualidade da tese. Gratidão às minhas amigas da UFSJ as quais por um feliz destino vieram fazer doutorado também na EERP Camila Matias e Aline Silva e que me acolheram em Ribeirão Preto pela primeira vez e generosamente me aceitaram no apartamento delas por um mês até eu me fixar na cidade.Muito obrigada à Letícia pela parceria desde o início tanto como companheira de apartamento em Ribeirão Preto, quanto de trabalho, fazendo todas as genotipagens deste estudo. Obrigada por tudo! Gratidão a todos os meus amigos de laboratório e que tive a oportunidade de conhecer e conviver de forma tão acolhedora, divertida e ética nesses anos de doutoramento na EERP.

show abstract

Efficacy of trial-based cognitive therapy, behavioral activation and treatment as usual in the treatment of major depressive disorder: preliminary findings from a randomized clinical trial

et al. 2019

Self Cite

View full text Add to dashboard Cite

Introduction. Major depressive disorder (MDD) is a prevalent, debilitating and disabling disorder, and its prevalence is increasing. Antidepressants (AD), cognitive-behavioral therapy (CBT) and behavioral activation (BA) are the main treatments for MDD. Trial-based cognitive therapy (TBCT) addresses and restructures dysfunctional negative core beliefs (CBs) and is a novel and promising approach. Objective. The aim of this study was to compare the efficacy of TBCT, BA and treatment as usual (TAU) in the treatment of MDD. Methods. A total of 76 patients with MDD were randomized into 1 of 3 groups and evaluated at baseline, after 6 weeks and at week 12 (final evaluation). The primary outcome was changing in HAM-D scores, and the secondary outcomes included scores on the BDI, CD-Quest, Sheehan Disability Scale (SDS) and WHOQOL. Results. Both TBCT and BA (which also included AD) were different from TAU (which included antidepressants alone) in reducing the HAM-D and BDI scores and other measures. TBCT and BA were different from TAU in the reduction of disability in SDS and WHOQOL physical domain scores. Besides limited by a small sample size, the dropout rate in the TAU arm was higher, and only 10 patients completed the 3 evaluations. Conclusion. This trial provides evidence that TBCT and BA combined with antidepressants were more efficacious than the TAU (drug alone) in reducing the severity of depressive symptoms and disability, showing that this combination can be useful for clinical practice.

show abstract

GRID Hamilton Rating Scale For Depression--Brazilian Portuguese Version

Cited by 5 publications

References 0 publications

Pharmacogenetics and therapeutic drug monitoring of fluoxetine in a real-world setting: A PK/PD analysis of the influence of (non-)genetic factors.

Pharmacogenetics and therapeutic drug monitoring of fluoxetine in a real-world setting: A PK/PD analysis of the influence of (non-)genetic factors.

Estudo de associação entre polimorfismos genéticos e níveis plasmáticos do VEGF, FLT1, KDR e o risco para depressão

Efficacy of trial-based cognitive therapy, behavioral activation and treatment as usual in the treatment of major depressive disorder: preliminary findings from a randomized clinical trial

Contact Info

Product

Resources

About